isoc1 Antibody

What is ISOC1 and what is its significance in biomedical research?

ISOC1 is an isochorismatase domain-containing protein that has gained attention as a potential biomarker and functional contributor in cancer development. Recent studies have demonstrated its role in non-small cell lung cancer (NSCLC), where it significantly promotes cell proliferation, migration, and invasion . ISOC1 has been reported as a potential biomarker in gastrointestinal cancer, with emerging evidence suggesting its involvement in tumor progression mechanisms . The protein contains specific domains that make it targetable for antibody-based detection and research applications, enabling researchers to investigate its expression and function in various experimental contexts.

What types of ISOC1 antibodies are currently available for research?

Several types of ISOC1 antibodies are available for research purposes, varying in their targeted epitopes, host species, and conjugations. Available options include:

• Polyclonal antibodies targeting specific regions (AA 155-298, AA 43-204, C-Term)

• Unconjugated antibodies for flexible application

• Conjugated versions with fluorescent tags (FITC), enzymes (HRP), or affinity molecules (Biotin)

• Antibodies with different species reactivity profiles, including those reactive with human ISOC1 only, and those with cross-reactivity to multiple species (cow, dog, guinea pig, horse, mouse, rat, monkey, pig, and Xenopus laevis)

When selecting an ISOC1 antibody, researchers should consider the specific epitope recognition, species reactivity, and conjugation status based on their experimental requirements.

What are the primary applications for ISOC1 antibodies?

ISOC1 antibodies are utilized in multiple research applications, with the most common being:

• Western Blotting (WB): For detecting and quantifying ISOC1 protein expression in cell or tissue lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of ISOC1 in solution

• Immunohistochemistry (IHC): For visualizing ISOC1 expression patterns in tissue sections

• Co-immunoprecipitation (Co-IP): For studying protein-protein interactions with ISOC1, as demonstrated in studies utilizing FLAG-tagged ISOC1 constructs

• Flow cytometry: When using fluorophore-conjugated versions for cellular analysis

These applications provide researchers with complementary approaches to investigate ISOC1 expression, localization, and function in various experimental systems.

How should I design experiments to investigate ISOC1 function in cancer models?

When designing experiments to investigate ISOC1 function in cancer models, a comprehensive approach utilizing genetic manipulation techniques is recommended:

• Expression modulation strategies:

  • Overexpression: Clone full-length ISOC1 into expression vectors (e.g., pCDH-CMV-MCS-EF1-GFP+Puro) to study gain-of-function effects

  • Knockdown: Design short hairpin RNAs (shRNAs) targeting ISOC1 and clone into appropriate vectors (e.g., LentiLox 3.7) to study effects of reduced expression

  • Knockout: Implement CRISPR/Cas9 system with specific sgRNAs designed using specialized tools (e.g., http://crispr.mit.edu/) to completely eliminate ISOC1 expression

• Functional assays:

  • Cell proliferation: Utilize assays such as CCK-8 to measure ISOC1's impact on cancer cell growth

  • Migration and invasion: Employ Transwell assays to assess the role of ISOC1 in cancer cell motility and invasiveness

  • Colony formation: Evaluate the effect of ISOC1 on anchorage-independent growth

  • In vivo models: Conduct xenograft tumor growth assays using ISOC1-modified cells (e.g., WT vs. ISOC1 KO) in appropriate animal models to assess tumorigenic potential

• Mechanism exploration:

  • Cell cycle analysis: Examine how ISOC1 affects cell cycle distribution

  • Protein interaction studies: Perform co-immunoprecipitation combined with mass spectrometry to identify ISOC1-interacting proteins

  • Transcriptome analysis: Conduct RNA sequencing to uncover changes in gene expression profiles following ISOC1 modulation

This multi-faceted approach allows for comprehensive characterization of ISOC1's functional role in cancer development and progression.

What controls should I include when using ISOC1 antibodies in my experiments?

Implementing appropriate controls is critical for ensuring the validity and reproducibility of experiments using ISOC1 antibodies:

• For Western blotting and immunohistochemistry:

  • Positive control: Include samples known to express ISOC1 (e.g., A549 cells for lung cancer studies)

  • Negative control: Use samples where ISOC1 is knocked out via CRISPR/Cas9 or knocked down via shRNA

  • Loading control: Include antibodies against housekeeping proteins (e.g., GAPDH, β-actin) to normalize protein loading

  • Secondary antibody-only control: Omit primary antibody to assess non-specific binding of secondary antibody

• For flow cytometry:

  • Fluorescence Minus One (FMO) controls: Include samples with all fluorochromes except the one conjugated to the ISOC1 antibody to establish proper gating strategies

  • Blocking controls: Pre-incubate cells with unconjugated blocking antibody before adding fluorescently-labeled ISOC1 antibody to assess specific binding

  • Isotype controls: Use antibodies of the same isotype, fluorochrome, and fluorophore/protein (F/P) ratio as the ISOC1 antibody, preferably from the same manufacturer

• For co-immunoprecipitation:

  • Input control: Reserve a portion of the pre-immunoprecipitation lysate to confirm the presence of target proteins

  • IgG control: Use non-specific IgG of the same species as the ISOC1 antibody to assess non-specific binding

  • Reciprocal IP: If studying interaction between ISOC1 and another protein, perform IP with antibodies against both proteins

These controls help ensure experimental rigor and facilitate proper interpretation of results when working with ISOC1 antibodies.

How can I validate the specificity of my ISOC1 antibody?

Validating antibody specificity is crucial for obtaining reliable research data. For ISOC1 antibodies, consider the following validation approaches:

• Genetic validation:

  • Compare antibody reactivity in wild-type cells versus ISOC1 knockout cells generated using CRISPR/Cas9 technology

  • Assess staining in cells where ISOC1 is knocked down using specific shRNAs targeting different regions of the ISOC1 mRNA

  • Evaluate staining in cells overexpressing ISOC1 compared to control vector-transduced cells

• Biochemical validation:

  • Perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide before application to samples

  • Use multiple antibodies targeting different epitopes of ISOC1 and compare detection patterns

  • Perform mass spectrometry confirmation of immunoprecipitated proteins to verify ISOC1 identity

• Expression pattern validation:

  • Compare antibody staining patterns with known subcellular localization of ISOC1

  • Correlate protein detection with mRNA expression data from RT-qPCR or RNA sequencing

  • Confirm expected molecular weight on Western blots and assess for presence/absence of non-specific bands

Thorough validation using multiple approaches provides confidence in antibody specificity and strengthens the reliability of experimental findings.

How can I optimize ISOC1 detection in challenging samples?

Detecting ISOC1 in challenging samples may require optimization strategies:

• For formalin-fixed paraffin-embedded (FFPE) tissues:

  • Optimize antigen retrieval methods (heat-induced epitope retrieval using citrate or EDTA buffers at various pH levels)

  • Test different antibody concentrations and incubation times/temperatures

  • Employ signal amplification systems such as tyramide signal amplification (TSA)

  • Consider using antibodies targeting epitopes less affected by fixation (e.g., C-terminal regions)

• For low-expressing samples:

  • Implement more sensitive detection methods like chemiluminescence for Western blotting

  • Use biotin-streptavidin amplification systems for immunohistochemistry

  • Consider antibodies conjugated to brighter fluorophores for flow cytometry or immunofluorescence

  • Use immunoprecipitation to concentrate the protein before detection

• For high background samples:

  • Optimize blocking conditions using various blockers (BSA, non-fat dry milk, normal serum)

  • Increase washing stringency (higher salt concentration, longer wash times)

  • Use monovalent Fab fragments to block endogenous immunoglobulins in tissue samples

  • Consider pre-adsorption of antibodies against tissues or lysates lacking the target

These optimization strategies can significantly improve ISOC1 detection in various challenging experimental contexts.

What are the considerations for using ISOC1 antibodies in multi-parameter flow cytometry?

Multi-parameter flow cytometry with ISOC1 antibodies requires careful planning:

• Panel design considerations:

  • Select appropriate fluorochrome combinations based on instrument capabilities and antigen expression levels

  • For intracellular ISOC1 detection, pair with bright fluorochromes if expression is low, or less bright fluorochromes if expression is high

  • Consider spectral overlap when selecting fluorochromes and implement proper compensation controls

  • Plan antibody panel carefully to avoid fluorescence spillover between channels

• Control requirements:

  • Include FMO controls for each fluorochrome to establish proper gating strategies

  • Use isotype controls with the same fluorochrome and F/P ratio as the ISOC1 antibody, particularly when assessing shifts in fluorescence intensity

  • Implement blocking controls to minimize non-specific binding, especially when Fc receptors may be present

• Sample preparation protocol:

  • Optimize fixation and permeabilization conditions for intracellular ISOC1 detection

  • Ensure consistent cell concentrations and staining volumes across samples

  • Standardize incubation times and temperatures for all antibodies in the panel

  • Consider sequence of antibody addition (surface markers before fixation/permeabilization for intracellular targets)

Careful attention to these details facilitates successful incorporation of ISOC1 antibodies into multi-parameter flow cytometry experiments.

How can I quantify free cysteine residues in ISOC1 for structural studies?

For structural studies requiring quantification of free cysteine residues in ISOC1, several sophisticated methodologies can be employed:

• Fluorescent labeling approach:

  • Treat ISOC1 with 5-iodoacetamidofluorescein (5-IAF) under partially denaturing conditions (4M guanidine hydrochloride) to expose all free sulfhydryl groups

  • Use a 10:1 5-IAF:protein ratio to ensure efficient alkylation and 'fix' the redox state of free cysteines

  • Differentiate remaining disulfide-bonded cysteines by reacting with iodoacetic acid (IAA) after full denaturation and reduction

  • Analyze by MALDI-Tof MS to quantify free cysteines (each 5-IAF modification gives a mass shift of 387.4 Da)

  • Determine localization by digesting with trypsin, separating peptides by RP-HPLC with fluorescence detection, and analyzing collected peaks by MALDI-Tof MS

• Isotope labeling strategy:

  • Utilize differential labeling with 12C-iodoacetic acid (12C-IAA) and 13C-iodoacetic acid (13C-IAA)

  • The 2 Da mass shift between labels allows identification and distinction between free cysteines originally present and those liberated from denaturation and reduction

  • Perform LC-MS after multi-enzyme digest (trypsin, Lys-C, chymotrypsin, Asp-N, or Glu-C)

  • Identify MS peaks for each peptide from calculated masses of the peptide sequence plus cysteine modifications

  • Calculate peptide isotope peak areas from MS1 spectra for both 12C-IAA and 13C-IAA peptide adducts to determine relative percentages of each form

  • This approach can accurately quantify down to 0.5% free cysteine for each peptide

These advanced methodologies provide detailed information about the number, location, and structural context of free cysteine residues in ISOC1, which can be valuable for understanding protein structure-function relationships.

Why might I observe inconsistent results with ISOC1 antibodies?

Inconsistent results with ISOC1 antibodies can stem from several factors:

• Antibody-related factors:

  • Lot-to-lot variability: Different production batches may have varying affinities or specificities

  • Antibody degradation: Improper storage or repeated freeze-thaw cycles can impact performance

  • Epitope accessibility: The targeted region might be differentially accessible depending on experimental conditions

  • Cross-reactivity: Some antibodies may recognize related proteins, especially in different species

• Sample preparation issues:

  • Inconsistent fixation/permeabilization: Variations in fixation time or permeabilization efficiency

  • Protein degradation: Inadequate protease inhibition during sample preparation

  • Post-translational modifications: Different cellular states may alter ISOC1 modifications and epitope recognition

  • Extraction conditions: Various buffers may differentially extract ISOC1 from cellular compartments

• Experimental variables:

  • Cellular heterogeneity: Varying expression levels across different cell populations

  • Cell culture conditions: Different culture states (confluency, passage number) affecting expression

  • Incubation conditions: Variations in temperature, time, or antibody concentration between experiments

  • Detection system sensitivity: Inconsistencies in detection reagents or imaging parameters

Systematic troubleshooting of these factors can help identify sources of variability and improve reproducibility in ISOC1 antibody-based experiments.

How should I interpret changes in ISOC1 expression in disease models?

Interpreting changes in ISOC1 expression in disease models requires careful consideration of multiple factors:

• Context-dependent interpretation:

  • Compare expression changes with functional outcomes (proliferation, migration, invasion)

  • Consider cell type-specific effects, as ISOC1 may have different roles in different tissues

  • Assess correlation with disease stage or progression to establish clinical relevance

  • Evaluate concordance between protein and mRNA expression changes

• Causality assessment:

  • Determine whether ISOC1 changes are driving disease or are secondary effects

  • Perform genetic manipulation experiments (overexpression, knockdown, knockout) to establish cause-effect relationships

  • Conduct rescue experiments to confirm specificity of observed phenotypes

  • Integrate findings with known signaling pathways and molecular mechanisms

• Translational significance evaluation:

  • Compare findings across multiple disease models and human samples

  • Assess potential as a biomarker by correlating with clinical parameters

  • Consider therapeutic implications (e.g., would targeting ISOC1 affect disease outcomes?)

  • Evaluate reproducibility across independent studies and experimental approaches

Comprehensive interpretation considering these aspects provides more meaningful insights into the biological and clinical significance of ISOC1 expression changes in disease contexts.

What are common pitfalls in analyzing ISOC1 function in cancer research?

Researchers should be aware of several common pitfalls when analyzing ISOC1 function in cancer research:

Awareness of these pitfalls and implementing strategies to address them enhances the robustness and reliability of research findings related to ISOC1 function in cancer.

What emerging technologies might enhance ISOC1 research?

Several emerging technologies hold promise for advancing ISOC1 research:

• Advanced imaging approaches:

  • Super-resolution microscopy for detailed subcellular localization studies

  • Live-cell imaging using fluorescently tagged ISOC1 to track dynamic localization and interactions

  • Spatial transcriptomics combined with protein detection to correlate ISOC1 expression with tissue microenvironment

  • Multiplexed ion beam imaging (MIBI) or imaging mass cytometry for simultaneous detection of ISOC1 and multiple markers

• Multi-omics integration:

  • Combined proteomics, transcriptomics, and metabolomics approaches to place ISOC1 in broader cellular networks

  • Phosphoproteomics to identify ISOC1 post-translational modifications and signaling connections

  • Single-cell multi-omics to understand ISOC1 heterogeneity within tissues

• Structural biology advances:

  • Cryo-electron microscopy for high-resolution ISOC1 structure determination

  • Hydrogen-deuterium exchange mass spectrometry to study ISOC1 protein dynamics

  • Computational structure prediction using AlphaFold2 or similar algorithms to generate ISOC1 structural models

These technologies can provide deeper insights into ISOC1 biology and potentially reveal new therapeutic opportunities.

How might ISOC1 research translate to clinical applications?

The translation of ISOC1 research to clinical applications may proceed along several pathways:

• Diagnostic applications:

  • Development of ISOC1-based biomarkers for early cancer detection

  • Integration of ISOC1 expression into multi-marker diagnostic panels

  • Creation of imaging probes targeting ISOC1 for cancer visualization

• Prognostic tools:

  • Establishment of ISOC1 expression profiles as predictors of disease progression or treatment response

  • Incorporation of ISOC1 status into existing prognostic algorithms

  • Development of companion diagnostics for ISOC1-targeted therapies

• Therapeutic strategies:

  • Design of small molecule inhibitors targeting ISOC1 enzymatic activity

  • Development of proteolysis-targeting chimeras (PROTACs) to induce ISOC1 degradation

  • Creation of ISOC1-targeting antibody-drug conjugates for cancer therapy

  • Exploration of synthetic lethality approaches involving ISOC1 and related pathways

The progression from basic ISOC1 research to clinical applications requires continued mechanistic studies, validation across diverse patient cohorts, and development of targeted intervention strategies.